Abbott Laboratories (ABT)

The sleeper story isn't the nutrition spin, it's that Abbott just cut full-year sales guidance for the first time this cycle while simultaneously letting Structural Heart, a segment with an explicit prior commitment, vanish from the call entirely. The binding constraint is forecasting discipline, not demand: management admits the EP cut caught them off guard ('So when I got that, I was like, really?'), diabetes has now been cut twice in two quarters, and 2027 guidance went from an anchored '7% is still the right target' to an unanchored 'pretty similar to this year.' Ford's own words on the spin rationale, pre-empting a Barron's story he says 'got it totally wrong,' suggest he's fighting a narrative he knows is vulnerable. My view changes if January guidance reinstates a specific, anchored 2027 number with Structural Heart restored to the disclosure set; if it stays buried, this is a company managing optics through a messy transition, not executing from strength.